<SEC-DOCUMENT>0001655759-24-000113.txt : 20240730
<SEC-HEADER>0001655759-24-000113.hdr.sgml : 20240730
<ACCEPTANCE-DATETIME>20240730073309
ACCESSION NUMBER:		0001655759-24-000113
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240730
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240730
DATE AS OF CHANGE:		20240730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38672
		FILM NUMBER:		241154395

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>arvn-20240730.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1b0c50ce-4411-402f-a7c4-3a0b49f33b8d,g:da005ab1-91ae-47d5-964b-3be8fa77823d,d:77e047154efc4ed885cbed101ecfd5cd-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arvn-20240730</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001655759</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arvn-20240730.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-30</xbrli:startDate><xbrli:endDate>2024-07-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i77e047154efc4ed885cbed101ecfd5cd_1"></div><div style="min-height:21.6pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July&#160;30, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Arvinas, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-2566120</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">5 Science Park</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">395 Winchester Ave.</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">New Haven</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">06511</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">203</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">535-1456</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div style="margin-bottom:1pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:38.808%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.868%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.812%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">ARVN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i77e047154efc4ed885cbed101ecfd5cd_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">July&#160;30, 2024</ix:nonNumeric>, Arvinas, Inc. announced its financial results for the quarter ended June&#160;30, 2024 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="i77e047154efc4ed885cbed101ecfd5cd_10"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"/><td style="width:8.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.057%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="arvn-20240730xexx991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="arvn-20240730xexx991.htm">Press Release issued by the Registrant on July 30, 2024.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (formatted as Inline XBRL).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i77e047154efc4ed885cbed101ecfd5cd_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:46.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ARVINAS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: July&#160;30, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Andrew Saik</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Andrew Saik</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>arvn-20240730xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie72f154b00ad4e67952a606131ed3c0e_1"></div><div style="min-height:90pt;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211; Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting&#59; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+&#47;HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting&#8211;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211;  Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24&#47;1Q25 &#8211;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211; Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis&#59; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties &#8211;</font></div><div><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211; Strengthened executive team with the appointment of Andrew Saik as Chief Financial Officer and the promotions of Ian Taylor to President of R&#38;D, Angela Cacace to Chief Scientific Officer, and Randy Teel to Chief Business Officer &#8211; </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#3c3c3c;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NEW HAVEN, Conn., July 30, 2024 --</font><font style="color:#3c3c3c;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Arvinas, Inc. (Nasdaq&#58; ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;During the second quarter, we continued making meaningful progress across our entire portfolio, with upcoming milestones that will further support our mission to improve patient lives with pioneering therapies from our revolutionary PROTAC&#174; protein degradation platform,&#8221; said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. &#8220;The readout of VERITAC-2, our first Phase 3 clinical trial, will be a landmark event for Arvinas. We are on-track to complete enrollment in the fourth quarter of the year, with topline data anticipated in either the fourth quarter of 2024 or first quarter of 2025. If positive, we believe these results will support our first new drug application filing and our transition to a commercial-stage company, assuming regulatory approval.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We are well on our way to becoming a multi-product, commercial-stage organization with strong leadership and a robust pipeline across several indications,&#8221; continued Dr. Houston. &#8220;Our first PROTAC degrader with the potential to treat neurodegenerative diseases, ARV-102, was recently cleared to initiate the multiple ascending dose portion of our Phase 1 clinical trial. In addition, we initiated the first-in-human Phase 1 clinical in trial patients with B-cell lymphomas with our PROTAC BCL6 degrader ARV-393. I&#8217;m excited by the progress we have made and the ongoing confidence we have in our PROTAC platform, which was further validated by our recent strategic transaction with Novartis. We believe Novartis will accelerate and broaden the development of ARV-766 as a potential best-in-class treatment for patients with prostate cancer.&#8221; </font><font style="color:#3c3c3c;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Recent Developments and 2Q Business Highlights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Vepdegestrant</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Evaluated enrollment and blinded event rates in the ongoing VERITAC-2 Phase 3 monotherapy clinical trial (NCT05654623) in patients with metastatic breast cancer.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.9pt">The trial is on track to complete enrollment in 4Q24.Based on current trial status, the primary completion date has been reprojected to November 2024, with topline data now anticipated in 4Q24&#47;1Q25.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Completed enrollment of the study lead-in for the VERITAC-3 Phase 3 clinical trial of vepdegestrant in combination with palbociclib as a first-line treatment in patients with </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">estrogen receptor (ER) positive&#47;human growth epidermal growth factor 2 (HER2) negative (ER+&#47;HER2-) locally advanced or metastatic breast cancer.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+&#47;HER2- metastatic breast cancer.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Presented updated clinical data from a Phase 1b clinical trial combination cohort evaluating vepdegestrant in combination with palbociclib in heavily pre-treated patients with locally advanced or metastatic ER+&#47;HER2- breast cancer at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.9pt">After six months of additional follow-up, updated data from the trial continued to demonstrate an encouraging clinical benefit rate, objective response rate and progression-free survival, and a consistent safety profile as previously reported at the San Antonio Breast Cancer Symposium (SABCS) in December 2023.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.9pt">The clinical benefit rate across all dose levels (n&#61;46) was 63%&#59; the objective response rate in evaluable patients with measurable disease at baseline (n&#61;31) was 42%&#59; median progression-free survival based on 27 (59%) events across all dose levels was 11.2 months (95% CI&#58; 8.2 &#8211; 16.5) and the safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.9pt">Patients receiving the recommended Phase 3 dose of vepdegestrant (200mg) in combination with palbociclib 125mg (n&#61;21), achieved a median progression-free survival of 13.9 months (95% CI&#58; 8.1-NR).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Strategic Transaction with Novartis</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Entered into a license agreement and asset purchase agreement with Novartis (NYSE&#58; NVS) for the exclusive, worldwide development, manufacture and commercialization of ARV-766, Arvinas&#8217; second generation PROTAC&#174; androgen receptor (AR) degrader for patients with prostate cancer, and the sale of Arvinas&#8217; preclinical AR-V7 program, which closed on May 28, 2024.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.9pt">Arvinas received a one-time, upfront payment in the aggregate amount of $150.0 million in accordance with the terms of the license agreement and the asset purchase agreement. Under the terms of the license agreement, Arvinas is also eligible to receive up to an additional $1.01 billion as contingent payments based on specified development, regulatory, and commercial milestones for ARV-766 being met, as well as tiered royalties based upon worldwide net sales of ARV-766.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Pipeline</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ARV-102&#58; Oral PROTAC LRRK2 degrader</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Presented preclinical data at the Biennial International LRRK2 Meeting further supporting the potential of PROTAC-induced leucine-rich repeat kinase 2 (LRRK2) degradation as a potential treatment for neurodegenerative diseases. Key findings included&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.9pt">With Arvinas' PROTAC LRRK2 degrader, near-complete LRRK2 target engagement, as well as LRRK2 degradation, in mouse and non-human primate lung and brain.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.9pt">Differing effects of the LRRK2 PROTAC degraders in the lungs compared to kinase inhibitors, suggesting reduced pulmonary function risk.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">Substantially less Type II pneumocyte enlargement compared to MLi-2, an experimental LRRK2 kinase inhibitor.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">Surfactant protein accumulation in mouse lung observed after treatment with the LRRK2 kinase inhibitor MLi-2, but not after treatment with the PROTAC LRRK2 degrader. </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">No evidence of collagen deposition in lung to date with PROTAC LRRK2 degraders in non-human primates.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">Received health authority approval to initiate the multiple ascending dose portion of the ongoing Phase 1 clinical trial in healthy volunteers with the PROTAC LRRK2 degrader ARV-102.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ARV-393&#58; Oral PROTAC BCL6 degrader</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Presented preclinical data for ARV-393 at the European Hematology Association 2024 Annual Congress that showed ARV-393&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.9pt">Potently and rapidly degraded the BCL6 protein and inhibited cell growth in diffuse large B-cell lymphoma (DLBCL) and Burkitt cell lines. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.9pt">Showed tumor growth inhibition, including tumor regression, in various DLBCL cell line-derived xenograft (CDX) models and in multiple patient-derived xenograft (PDX) models of non-Hodgkin lymphoma (NHL), including germinal center B-cell-like (GCB), activated B-cell (ABC), GCB&#47;ABC, BCL not otherwise specified (BCL&#47;NOS) subtypes of DLBCL, and Burkitt lymphoma.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:14.15pt">Initiated the first-in-human Phase 1 clinical trial in patients with B-cell lymphomas with PROTAC BCL6 degrader ARV-393.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Corporate</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Announced the appointment of Andrew Saik, MBA, to the role of Chief Financial Officer.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Announced the promotion of Ian Taylor, Ph.D., to President of Research and Development.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Announced the promotion of Angela Cacace, Ph.D., to Chief Scientific Officer.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Announced the promotion of Randy Teel, Ph.D., to Chief Business Officer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Anticipated Upcoming Milestones and Expectations</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Vepdegestrant (ARV-471)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As part of Arvinas&#8217; global collaboration with Pfizer, the companies plan to&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Complete enrollment (4Q24) and announce topline data (4Q24&#47;1Q25) for the VERITAC-2 Phase 3 monotherapy clinical trial.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Evaluate data from the study lead-in of the VERITAC-3 Phase 3 trial to support dose selection for vepdegestrant plus palbociclib in planned Phase 3 combination trials in patients with ER+&#47;HER2- locally advanced or metastatic breast cancer (2H24).</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Present initial safety and pharmacokinetic data from the abemaciclib arm of the ongoing TACTIVE-U trial (2H24). </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Continue enrollment of the ongoing Phase 1b&#47;2 combination umbrella trial evaluating combinations of vepdegestrant with abemaciclib, ribociclib, or samuraciclib (TACTIVE-U&#59; ClinicalTrials.gov Identifiers&#58; NCT05548127, NCT05573555, and NCT06125522).</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">Continue enrollment and evaluate preliminary data from the ongoing clinical trial with vepdegestrant plus Pfizer&#8217;s novel CDK4 inhibitor atirmociclib (TACTIVE-K&#59; ClinicalTrials.gov Identifier&#58; NCT06206837) to inform the study design for the planned Phase 3 first line combination trial with either atirmociclib or palbociclib, with planned initiation in 2025. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Pipeline</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Continue enrollment in the single ascending dose portion of the Phase 1 clinical trial in healthy volunteers with the PROTAC LRRK2 degrader ARV-102 and begin enrolling the multiple ascending dose portion by the end of 2024.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Continue enrollment in the first-in-human Phase 1 clinical trial in patients with B-cell lymphomas with PROTAC BCL6 degrader ARV-393.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Financial Guidance </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Based on its current operating plan, Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of June&#160;30, 2024, is sufficient to fund planned operating expenses and capital expenditure requirements into 2027.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Second Quarter Financial Results</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Marketable Securities Position&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;As of June&#160;30, 2024, cash, cash equivalents, restricted cash and marketable securities were $1,234.2 million as compared with $1,266.5 million as of December&#160;31, 2023. The decrease in cash, cash equivalents, restricted cash and marketable securities of $32.3 million for the six months ended June&#160;30, 2024 was primarily related to cash used in operations of $36.0 million (net of $150.0 million received from the Novartis agreements), unrealized losses on marketable securities of $0.7 million and the purchase of lab equipment and leasehold improvements of&#160;$0.8 million, partially offset by proceeds from the exercise of stock options of $5.3 million. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Research and development expenses were $93.7&#160;million for the quarter ended June&#160;30, 2024, as compared with $103.4&#160;million for the quarter ended June&#160;30, 2023. The decrease in research and development expenses of $9.7&#160;million for the quarter was primarily due to decreases in expenses related to our ER program (which includes the cost sharing of&#160;vepdegestrant under the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer) of $6.6&#160;million and our platform and exploratory programs of $5.7&#160;million, partially offset by an increase in our AR program (which includes ARV-766 and bavdegalutamide (ARV-110)) of $2.6&#160;million.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General and Administrative Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;General and administrative expenses were $31.3&#160;million for the quarter ended June&#160;30, 2024, as compared with $25.7&#160;million for the quarter ended June&#160;30, 2023. The increase in general and administrative expenses of $5.6&#160;million for the quarter was primarily due to an increase in personnel and infrastructure related costs of $4.0&#160;million and professional fees of $1.6&#160;million.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Revenues were $76.5&#160;million for the quarter ended June&#160;30, 2024 as compared with $54.5&#160;million for the quarter ended June&#160;30, 2023. Revenue for the quarter is related to the license agreement and the asset purchase agreement with Novartis, the&#160;Vepdegestrant (ARV-471)&#160;Collaboration Agreement with Pfizer, the collaboration and license agreement with Bayer, the collaboration and license agreement with Pfizer, and revenue related to our Oerth Bio joint venture. The increase in revenue of $22.0&#160;million was primarily due to revenue from the Novartis agreements, which were entered into during the quarter, of $45.4&#160;million, offset by a decrease in revenue from the&#160;Vepdegestrant (ARV-471)&#160;Collaboration Agreement with Pfizer of $22.2&#160;million and a decrease of $1.3&#160;million of previously constrained deferred revenue related to our Oerth Bio joint venture.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Vepdegestrant</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER positive (ER+)&#47;human epidermal growth factor receptor 2 (HER2) negative (ER+&#47;HER2-) breast cancer. Vepdegestrant is being </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+&#47;HER2- metastatic breast cancer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant&#59; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+&#47;HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Arvinas</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Arvinas (Nasdaq&#58; ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC&#174; (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body&#8217;s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+&#47;HER2- breast cancer&#59; ARV-102, targeting LRRK2 for neurodegenerative disorders&#59; and ARV-393, targeting BCL6 for relapsed&#47;refractory non-Hodgkin Lymphoma. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">LinkedIn</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">X</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the expected timing in connection with the completion of enrollment and readout of topline data from the VERITAC-2 clinical trial, submission of Arvinas&#8217; first new drug application filing and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">transition to a commercial-stage company, assuming regulatory approval, the availability and timing of data from other clinical trials, the receipt of milestone and royalty payments in connection with the transaction with Novartis and the future development, potential marketing approval and commercialization of ARV-766, the potential of Arvinas&#8217; PROTAC protein degrader platform and its potential to deliver new treatments, Arvinas&#8217; and Pfizer&#8217;s plans to determine the recommended palbociclib dose to be combined with vepdegestrant in the planned Phase 3 combination trials in patients with ER+&#47;HER2- locally advanced or metastatic breast cancer, and statements regarding Arvinas&#8217; cash, cash equivalents, restricted cash and marketable securities. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas&#8217; strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to&#58; Arvinas&#8217; and Pfizer&#8217;s performance of the respective obligations with respect to Arvinas&#8217; collaboration with Pfizer&#59; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant&#59; whether Arvinas will be able to successfully conduct and complete development for its other product candidates and including whether Arvinas initiates and completes clinical trials for its product candidates and receive results from its clinical trials on its expected timelines or at all&#59; whether Arvinas and Pfizer, as appropriate, </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all&#59; Arvinas&#8217; and Novartis&#8217; performance of their respective obligations under the license agreement&#59; whether Novartis will be able to successfully conduct and complete clinical development, obtain marketing approval for and commercialize ARV-766&#59; Arvinas&#8217; ability to protect its intellectual property portfolio&#59; whether Arvinas&#8217; cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other important factors discussed in the &#8220;Risk Factors&#8221; section of Arvinas&#8217; Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas&#8217; current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas&#8217; views as of any date subsequent to the date of this release. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Contacts </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Investors&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Jeff Boyle</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">+1 (347) 247-5089 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">Jeff.Boyle&#64;arvinas.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media&#58; </font></div><div><font style="color:#3c3c3c;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Kathleen Murphy </font></div><div><font style="color:#3c3c3c;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">+1 (203) 584-0307 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">Kathleen.Murphy&#64;arvinas.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie72f154b00ad4e67952a606131ed3c0e_4"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arvinas, Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets (Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">154.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">311.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,073.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">949.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other receivables</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,256.7&#160;</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,280.2&#160;</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, equipment and leasehold improvements, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">9.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease right of use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Collaboration contract asset and other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total assets</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,279.6&#160;</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,304.6&#160;</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">78.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">92.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">267.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">163.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current portion of operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">347.2&#160;</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">257.1&#160;</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">331.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">386.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">679.4&#160;</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">644.6&#160;</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.001 par value, zero shares issued and outstanding as of June&#160;30, 2024 and December&#160;31, 2023, respectively</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $0.001 par value&#59; 68.6 and 68.0 shares issued and outstanding as of June&#160;30, 2024 and December&#160;31, 2023, respectively</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1,437.3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1,332.7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,041.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,995.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3.8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">600.2&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">660.0&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,279.6&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,304.6&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie72f154b00ad4e67952a606131ed3c0e_7"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arvinas, Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations (Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">76.5&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">54.5&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">101.8&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">87.0&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">93.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">103.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">178.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">198.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">25.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">55.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">50.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">125.0&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">129.1&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">233.6&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">249.3&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(48.5)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(74.6)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(131.8)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(162.3)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest and other income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">9.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">27.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss before income taxes and loss from equity method investment</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(35.0)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(65.6)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(104.2)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(146.8)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax (expense) benefit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(0.2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(0.3)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Loss from equity method investment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1.3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2.4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(35.2)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(66.6)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(104.6)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(148.5)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss per common share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(0.49)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1.25)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1.46)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2.78)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted average common shares outstanding, basic and diluted</font></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">71.9&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">53.4&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">71.7&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">53.4&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>arvn-20240730.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1b0c50ce-4411-402f-a7c4-3a0b49f33b8d,g:da005ab1-91ae-47d5-964b-3be8fa77823d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arvn="http://www.arvinas.com/20240730" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arvinas.com/20240730">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20240730_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20240730_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arvinas.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>arvn-20240730_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1b0c50ce-4411-402f-a7c4-3a0b49f33b8d,g:da005ab1-91ae-47d5-964b-3be8fa77823d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_43d643fb-ec60-45dc-b8fe-d4d81aef136b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5476cf0f-a022-4474-b2ad-d15e101ad6ab_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_18290750-1ac8-4d70-b3e7-c25fc3702f33_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_56ef8b98-bf29-4b62-9b95-27178379afa3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6411f063-20d0-4676-9e11-19e34d499ac6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ab20f34b-5a2e-4ff1-8d6b-74d21d067b6d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d537c327-a63c-4740-bf7b-5c1615bdf76f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_4ebc6be0-2dac-43f0-9b80-14d74bcd1ff3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_603e6be7-2573-4459-9b9b-6b00e0dffd10_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_17a2a1d1-a193-44d8-a22d-7e1f10d6c4d3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_95db0108-ae62-4d47-b185-daddd81705d0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_e3b04dc2-59ee-4ba8-ac5d-849de52708f5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_86b94a80-b54a-42cd-932b-d1bb1df9fcbd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c09d0e0f-dbfb-45a9-9dde-dcd1fb244046_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_650ad967-7684-4559-bb1f-fa06c0bc8a43_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_64923bf2-3514-4b2f-ae4f-998dd5e481b5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8f68b0e6-6e34-4b23-9b57-ca0e18884e3f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_03b1112c-10d4-4298-9453-c1fc922f3e12_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a37048a2-9e94-4d60-b43b-9826f884aece_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e65e69c9-1466-4d06-9604-5413393e580e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cc19c144-4ebf-4a40-a20d-d75a46576beb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_53db403d-4363-4d16-a87f-969451ee90e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bad17e74-1b46-42eb-820e-62fb30aaa0f0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>arvn-20240730_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1b0c50ce-4411-402f-a7c4-3a0b49f33b8d,g:da005ab1-91ae-47d5-964b-3be8fa77823d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/Cover" xlink:type="simple" xlink:href="arvn-20240730.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0ea961bb-6f99-414e-9b84-71860d6b08ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_DocumentType_0ea961bb-6f99-414e-9b84-71860d6b08ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_21f60c6a-b163-4c1c-8081-c93272054a13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_DocumentPeriodEndDate_21f60c6a-b163-4c1c-8081-c93272054a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_601730bb-21f7-40f5-a3db-5760ea568aee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityRegistrantName_601730bb-21f7-40f5-a3db-5760ea568aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_96853808-8b19-42bd-86b4-27df7183e820" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_96853808-8b19-42bd-86b4-27df7183e820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_94eed18c-fd87-4bd7-b331-99b41547300b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityFileNumber_94eed18c-fd87-4bd7-b331-99b41547300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4aebeaab-f4b0-41dd-ab08-1b97b95d04ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityTaxIdentificationNumber_4aebeaab-f4b0-41dd-ab08-1b97b95d04ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2fed8da8-a206-4b25-8d8f-ce692548e30c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityAddressAddressLine1_2fed8da8-a206-4b25-8d8f-ce692548e30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d6fb0fed-50d9-40de-b3b9-d98a2953ad5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityAddressAddressLine2_d6fb0fed-50d9-40de-b3b9-d98a2953ad5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a95efc25-6703-438e-80e4-497f659e39f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityAddressCityOrTown_a95efc25-6703-438e-80e4-497f659e39f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c86d3f6f-2247-4adb-9fbf-d0650f3f50c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityAddressStateOrProvince_c86d3f6f-2247-4adb-9fbf-d0650f3f50c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2c35cd83-9eba-483f-b25c-bd33b3f167af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityAddressPostalZipCode_2c35cd83-9eba-483f-b25c-bd33b3f167af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ee33a639-85fc-422d-935f-e555b71cdd3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_CityAreaCode_ee33a639-85fc-422d-935f-e555b71cdd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e5beef81-7860-404d-a75e-0093707eeffa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_LocalPhoneNumber_e5beef81-7860-404d-a75e-0093707eeffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a87ed49d-42c1-4557-b81a-46c1bbb7d359" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_WrittenCommunications_a87ed49d-42c1-4557-b81a-46c1bbb7d359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7d39c908-f457-4192-ba0e-1eb950837172" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_SolicitingMaterial_7d39c908-f457-4192-ba0e-1eb950837172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_22c6aac7-a420-4119-aef6-c39bbc60bbae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_PreCommencementTenderOffer_22c6aac7-a420-4119-aef6-c39bbc60bbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d7b90923-ea74-46ee-9ebb-02e4369b5d61" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d7b90923-ea74-46ee-9ebb-02e4369b5d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d81a9899-9e77-4891-8f40-ce8a6324ca53" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_Security12bTitle_d81a9899-9e77-4891-8f40-ce8a6324ca53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c40be7b5-9713-4fb0-82ac-bf802eac9c2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_TradingSymbol_c40be7b5-9713-4fb0-82ac-bf802eac9c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a5f80105-f227-4719-bff9-fe238891ce3f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_SecurityExchangeName_a5f80105-f227-4719-bff9-fe238891ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a0c9f52f-c2b8-407e-9906-851bb51c1e49" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityEmergingGrowthCompany_a0c9f52f-c2b8-407e-9906-851bb51c1e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a2539fac-1287-4b2e-a4ce-e3664b7d7406" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_EntityCentralIndexKey_a2539fac-1287-4b2e-a4ce-e3664b7d7406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7d7b93cc-a0b1-4018-9a07-eae9f0b11a9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bdb2883c-a870-4094-9181-45b8f7d767bb" xlink:to="loc_dei_AmendmentFlag_7d7b93cc-a0b1-4018-9a07-eae9f0b11a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" %M X # 2(  A$! Q$!_\0
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MEJD<!\N@"2.Y6X.U>U3 8&*S=+\T2G*]ZTATYH **** "BBB@ HHHH ****
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M;KQGTI(]+T?PZ?M+OM[]*0&TU*875NVY?6@"<(8$$I/49JQ#<+)'M/-07UQ
MD(4MT&*FT]8Y(MRT 30QJ#D#WJ2JFH-/&/W"YJ:S9VBS(.: ):*** "BBB@
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MM_LEOH94XQE=.8?TK],_^":O[6D?[6_PC_X3-("F84;!B*]?K7!V_P#P0?\
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MRFDWMZT]";CZ*:C$]:=0-.X4444#"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)J*K0:@D_*XYJR#D9K9IK<SC4C/8****184444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 131[FH,:JN1Z4LK8;I1+)L0,:F"]X*FL#
M-OK?S+@-CO5O8&@"@=J:2)/F S2P3+OVGUX%157/*Q%%<BN0ZA<1Z=ITMS*V
MT(N2:^<?VC?VL]&^&]E)(NL^6R*<_-BO8?CIXQB\.^ M3NBX4QP$YS7X=?\
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M*@'F$5X/^U_\:;#X::%.\TX3-L>K8ZBO9M;U=;'2WNI'VJHY8FOS!_X+1?M
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M:Q'LW>YS/CC1=(\0:--IT]A')YG4$5Y%H?[+/@Y]2DNKCPG;-NE+9,?O7O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140016542583520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arvinas, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2566120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Science Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">395 Winchester Ave.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-1456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARVN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001655759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD=N!XSMO#Y[X:FWL W?8S^B*S9CY/9LJ:+FE2LQ3)C27@BBV'#@C_^8V"&U
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( "0\_E@'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ )#S^6(P\_";N    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ )#S^6)E<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  D//Y8
M%3=7TED$   <$0  &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ )#S^6)^@&_"Q @  X@P   T
M     ( !G P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  D//Y8EXJ[',
M   3 @  "P              @ %X#P  7W)E;',O+G)E;'-02P$"% ,4
M"  D//Y8JL0B%C,!   B @  #P              @ %A$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ )#S^6"0>FZ*M    ^ $  !H
M ( !P1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M)#S^6&60>9(9 0  SP,  !,              ( !IA(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  \!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="arvn-20240730.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="arvn-20240730.htm">arvn-20240730.htm</File>
    <File>arvn-20240730.xsd</File>
    <File>arvn-20240730_lab.xml</File>
    <File>arvn-20240730_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arvn-20240730.htm": {
   "nsprefix": "arvn",
   "nsuri": "http://www.arvinas.com/20240730",
   "dts": {
    "inline": {
     "local": [
      "arvn-20240730.htm"
     ]
    },
    "schema": {
     "local": [
      "arvn-20240730.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "arvn-20240730_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arvn-20240730_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.arvinas.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20240730.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20240730.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001655759-24-000113-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001655759-24-000113-xbrl.zip
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M)S$T13,4W<@F@9'7ZV<Q-*U8P,=]&K)LN,/X;+0<F0$.#W#VXARXNV;5BPL
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M:J% '<,\@E!OFCT;0 ;EC_$]##LXYK AF)"4DD]$)SFCQ<%-<WL+RH6,/3%
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MU_GR> ^^;SSD@,+<0:Z1@@WV+75QZ6DX$D)*Z2P?JWM5W79I6#'5C;XTEK-
MLXJ[X:.1C[#[]O4Q":@@-]2-&?DWEC=U$N#)U^&W=7EN4+KOC!FIU4ULV(P3
MM5R]T?VS<V!4OCOY.K"N'AD'0"2\NTYD241RKN)V&PG:R>4.$D-#4QHZ].MM
M7I$>ZA#Y1,4UB\C'C\V[[-*V6^A[2D+:GH-I&"/]*;'E5AO =0U6E\F6U%O[
M8#PD "+D< CZ%;D2_C@:8C87X-X8#8G#!K"$/,21E)FU$ED]]#4_ZU4D>3R4
M5#F1I>9L,)?'/P(\_H';KDE*:/058\U<ZPZ0S2;%]'#^WL*TZF%O>K;NH/".
M^WG?7@UYT/FE#/KW$OAF OOF&R7T^PHA!ZH]@WOT 1M-UBH77]E?'H+J,!>R
M?5 =SY>Y?QPR.0HHG>YBXW4Q7-8#DEL>D*!R+7>*B\N;=U!(/, -G@AVPT-X
M#Q22>C86SJEMX^$/'(P7JCA4.&&R?^W<57@HYNFL\+"H:>J>1-'?02!>Q!;Q
MX5\FL7RM1^ G,F@)YE)LBENYZ&,.A%Q=F[]"^Q"(Q-'J*YON!MGUBI+*[(J2
MH9A'3E=,Z0M&KQ4Z !=@47=,IR'BO_X>$[/TL%M,;H5J"H955L7(8BVP"1 W
M60K^LJ<FK';$1L10-2,Y#[SZ=Y>%L1O)-LASL#5IE18L!GDW,R9-'XP;/MC*
ME9;W9J+/O6<_;&UN<]KZF"R=Y@7J>F"<;8R=@/)SHRU27J"Q1RO\-9;G8DGB
M%/Z(/;:\CF33S*AC=V-R?(B1.$#858*A\R!V72*O1$J->R#[7D&I&07'PW$;
M0T9Q=MH_C9EX=K5;!JHLY4-0-8B%Q\,A+H?QV)#W>41J-55'5R+#KF8L! Y.
M#\C#9%F_UE;2HS^'KJP7'R06]V:WM"%)-F!$\O/^TD5B'&%J#51'_]YG$"D#
M_1R";:H&(,!=YLC/^HED-7ACL)M,ZN#,&U>WC'^/D1%TE(A('E](EUD<G*YV
M=#P[@#:&>(&$<?\?6"]A'2,NIWWN)DO)Q2FDDPD\QX"*2)'BBSC-SZS!%PA]
M9K=S(?4P0DE;[N[L/TES@T4T))2WHY!C+&VQ0!X@9Q,IPMC<!PD9D!"$%=9.
MSY7;RT"$L0VQ4@K'&A'<\B8L;=U56)A**J!9@MJ1%<8CD./I4@,;EKX.W#G4
M5$V_RSG,78 \EX%&(/$-J;"'\]CP,#U"WCF:P[J#^7GF?;.R6BO7=@TGJVK%
M?)QC]560@5+E%>PK;5E0RDQUQU>_;??] '%[RT);\$">*_ZV5K[-A<5OKDP^
M:1O)+(1?PX+!X&F,#K @ <YA=GJ0VY*N#T<!3'2MYV")/)[L'4"RYN[-"9M,
M:C5='48@TAC<G!;HHYRG^\&YY^3<A0SZN\M!?S\Y%C$_287!+>8S)$LQU#NX
M_5UT!C\BZW)U73,?O]5K?^@T?0"%7%"(SMOH!$$;\-@D)-&4R-L=\DDB%26I
M8EN&2 3OFCY2=^C>6BS0O(AZ%)[@VW]!Z@"V[I*^M_;[3N/R<[?5VRI1V&/R
MOWC=8E*Q_QISD:8\VZ;B:TK]#EI3F\98GI?5A.1F0%P&LN@0. 0/_.0>M#Z#
M!'N0665IW-,!D+&SV(-WY'0TCH:^ .2<[?*O_20U#VH&-,MJM;1;?]U])[+N
M3VIV NI1^N[6.K_R@3?ZKD\T&MT_VYU&[YBT.\TU%GTE-M"?HOU\CS'$?4'J
MDWI>K%-;9%W5^6EB\GVUDTMD?YM:CQ\U[16C0E@@#<\1,%N/\NN'W*[Q.%KR
M:(U#B]V2ST]3[!U<1\^-C8][X'])'G+G;+"PN78N+QH1._<4'4AD7$C^/Q3Y
MGZC4_P]02P,$%     @ )#S^6%4423QK @  ;0<  !$   !A<G9N+3(P,C0P
M-S,P+GAS9,U5R6[;,!"]^RM8G4LMEE(OB!V@"0(4<!>D"9I;05$CFXA$JB1E
M.W]?DA;AR+&;&NBAOIB:>6^6QQGI\FI;5V@-4C'!9T$2Q@$"3D7!^'(6/-S?
MXG%P-1\,+M]A_/CQ;H%N!&UKX!I=2R :"K1A>H7T"M /(9_8FJ!O%=&ED#7&
M<T>[%LVS9,N51L-XF'F8]\IIDL?T(J: LRQ)<!8/2TQ&-,,IB?-L4J9I/B[>
M+Z<%B>,+DB=XDA"#'147>/(ARW&:P[@DH]%XF!8NZ%9-%5U!39!IC:OI5LV"
ME=;--(HVFTVX24,AE]$PCI/H\?/BNX,&';9B_*F'WN:R\O@TLNZ<*/!P(M>\
M!S<&QHD*J:@CVVT\2HV@1&O)\E;#K9'E!DK25GH6M/Q72RI6,BB,YA5857N
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M#;2IZ![@CL3'O#([OL^Y*,J;HFP6I8N*5>JTN,VK\N&TD&K*.(8Z)!Q$#"M
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M\0Q7.>XC,867A.N8<*438#C= 1A_ZL0@3N34.=F=SI/ YF-9P<]7:P]Y:25
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M)'SC\)]GUSW'^.5N[9MJ&23UH+TB5C-!9/*4&.ZP$$X&T77!!CZNO_#(W+#
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M$_?U3V/![=?_]=-_U^OLK6_%$^%%S H$CX3-XM#Q1NP/6X3?6+VNKKKRI[/
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MSAZIHBF/&;3NAR$;!OY$:PF^5_7-QF3<]EFCLW'[AC(QF1U:$4<#U%Z[T:V
M>F1 -5OF%MUO*JB6'*K=YA:]#$N@"Y2OL_VA7%D=;'6PAW5E=;#[.=@C2/+Y
M@%4](HQD:W/J7>AXEC]Y$9-&S=8^)V!5&0O%Z5=5)DDIX=+L50132L"8G6J6
MWQ.X)3^+B)KWLH$8^H%0HI%%_%[UWW,3OZ7LNL<F(AK[-EQX"T)UZVS98[.B
M6YV&44HC>K^N$3.WI\,!9[?S./_EBGU7@'Q6[Y;1;C0K2!X#)-O=QWF?GP"2
M+\%ZUOH .U%)3:>@*WABN.6PGP-3.T^,3=A'90H\!TR,;1,8*K@\-:UL$$BJ
M8/(\M%+-Q7G"X_WXI-;QH2#9WN>Z5@G_*_3F:E)AV6!2T4MY87/2;+2K:5)/
MX6)^1+KQICZ+<B@'CVG4LVK'9:2:5F<+.[D<;K;==96JT+3L:-KM;N+7K]"T
M0M.]12TJ/*WPM/1XNEGQSK/@Z?&G:DSE^.6)[\GQ!#4VX*%CR2YF#DZGLA\1
M)ELRONOH*&_S79>1^HQ&N_^8@.@#>]ZS<Z%"V2-$6;/1?%2Q9X6R>X?ART/9
M]J-2P2J4W3L,7QK*-AN]1V5*/1'*/K>'>_F\29EIJQ]:QR?0N=)3'1QU&9W7
M^T0DSZ+:XU"V/^@/83,.>^$CD5/O0^;'41B!=@_K7:7KR\FIV_<V66M^[S9<
MH"1TT3,;_4=U/MG% 1U0CLL+08O.UOV6*[0X8K0 ;K%EZE2%%D>,%@?-+4@#
M^Y&F9K]>',JM]MDF]4@/O ^$2WV>"P?)J_T8Z2U\$/JHF2S<4CBR/??OP+=G
M\&,<3=S7_P]02P$"% ,4    "  D//Y8!^4Y<$X/  !3:   $0
M    @ $     87)V;BTR,#(T,#<S,"YH=&U02P$"% ,4    "  D//Y8511)
M/&L"  !M!P  $0              @ %]#P  87)V;BTR,#(T,#<S,"YX<V10
M2P$"% ,4    "  D//Y82MT_!SL*   46   %0              @ $7$@
M87)V;BTR,#(T,#<S,%]L86(N>&UL4$L! A0#%     @ )#S^6% 8CZ+5!@
M]C(  !4              ( !A1P  &%R=FXM,C R-# W,S!?<')E+GAM;%!+
M 0(4 Q0    ( "0\_EB4U/FQ0RD  )>D 0 8              "  8TC  !A
M<G9N+3(P,C0P-S,P>&5X>#DY,2YH=&U02P4&      4 !0!* 0  !DT

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>arvn-20240730_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="arvn-20240730.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001655759</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-07-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Arvinas, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-2566120</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">5 Science Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">395 Winchester Ave.</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">535-1456</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">ARVN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2024-07-30</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
